REMINDER: Our user survey closes on Friday, please submit your responses here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Abbvie
Novartis talking about their bolt on M&A strategy.
Recently read they have abandoned their hemo phase 3 drug.
https://www.clinicaltrialsarena.com/news/sabotolimab-blood-cancer-pivotal-flop/
Sitting duck here guys with Gilead’s 47 failure, Abbie having a bad sae profile and Novartis potentially out of the game. Soooo cheap. Looking perkier in Helsinki today too…
https://x.com/bmhltd/status/1782674333631959408?s=46
Thanks for the welcome WG.
Yep, I’m aware of the lack of commercialisation there and I’ll be honest, an increase in death is not a good outcome. And you couldn’t rule that out for this, although the Matins trial was a decent size and there is a lot of safety data from all studies. Regarding the efficacy here, that looks very good and they are clearly confident about what’s to come. Patients who are likely to die within 4 months showing ORR’s be it PR CR mCR or hemo improvement is unlikely by chance even with the smallish numbers thus far, but they are ongoing too which bodes well and surpassing their expected prognosis for survival without any other options, ie the current status quo.
We only need cash to see us through the end of P2
(Jan 2025), FDA guidance for the pivotal pathway and I truly believe that will be enough to secure a decent £1-3bn offer (efficacy trend continuing).
Good to see support from the EIC. Hoping they don’t raise lower but with enough cash to see us to P2 read out and FDA pivotal guidance should be a huge value driver and trigger a positive re-rate regardless of price realised, AIMO.
I'm with you on this one Drac, Faron have treated the smaller long term investors apallingly over the so called "hiccup"- SP has not recovered to any significant extent, - some kind of explanation is the least we deserve. Maybe the larger institutional investors were given some some kind of reassurance and promise it would soon recover but we will never know..
Digitalman, A little Tetchy. Put your doom mongering back in your special box. My son and I Invested In Faron 5 years ago. We could have profited many times over that time. WE Don't trade the Co. We felt Faron had enormous potential going forward from All we were being told by Markku. My posts are my opinions with the added proviso IMO.
Bmhltd, the only gibberish Is your post. You say, Only Major risk I see Is cash position. Some risk. Get yourself up to speed on the actual Cash position. Read the 04 April 2024 RNS. Well where were the Big holders when Faron needed the cash and NOT allowed the Hiccup situation to happen. Faron LTSHs lost over half their SP value on that non decision. We never got any explanation on Why or How exactly that something so serious could be allowed happen. Your post Is very dependent on the usual Potential, Indication, sights on, likely,surely. WE SHs are years away from the SSV spoken of UNLESS Some Major Pharma show a serious Interest or complete a Deal with Faron. IMO.
Its worth pointing out that Gilead bought Forty Seven to get hold of Magrolimab , which at the time- 4 years ago- had gone through a promising phase 1B , for myelodysplastic syndrome (MDS) and acute myeloid leukemia What happened next is that the FDA approved a phase 2 , and subsequently a phase 3 for these conditions- they did not expedite any accelerated programme despite there being an unmet need scenario. This was in the face of serious lobbying from Gilead who are a USA company with a lot of financial clout. If you do your research you will find that The FDA has stopped the phase 3 trials https://www.gilead.com/news-and-press/company-statements/gilead-statement-on-discontinuation-of-phase-3-enhance-3-study-in-aml. This is due to a higher death rate in the treated cohort. The likelyhood of BEX getting an accelerated trial/ approval with a small cohort is Zero. If they went down this route every time a small phase 1 posted stunning results they would be killing people left right and centre, plus litigation would be unreal. As always a full one properly designed and approved phase 111 - if successful- is what is needed for approval.
Hi Bmhltd,welcome to the Faron board, I recently watched a recent presentation by Markku and the team,in.which it was stated that BP are far more wary of buying small clinical phase bio pharmas such as Faron following the take over of Forty Seven by Gilead,as they have yet to commercialise cd47 after 4 years.Hopefully Bex will be a much better bet.I believe that BP will need far more data so as to derisk their investment in smaller bio pharma companies. Anyway time will tell one way or another.
Likely be games along the way but sub £95m Mcap is a crazy valuation given what the big pharma will be willing to stump up soon. AIMO DYOR.
The guys talking utter gibberish.
Forty Seven was taken out by Gilead whilst in phase 1B for $4.9 billion.
Bex has all the potential that did. The first indication they have set there sights on, ie r/r MDS, is a quick win and a considerable market, which will likely receive Accelerated approval via a relatively small pivotal trial with a post-confirmatory trial while the product can be sold to help patients ASAP. The ORR thus far is exceptional, there are no other treatments and the FDA will want this expedited. AML will surely be their next target indication for approvals.
I’m buying what I can. Only major risk I see is cash position, but the big holders backing the company further suggests they are aligned, know the value and are willing to shoulder further risk for the potential reward. Buying in at this level is a real no-brainer, for me at least.
GLA and follow what the experts in the RNS’s are saying eg. Clinicians and hematologists ,who are not related to the company.
They are already into phase 2 so 4 to 5 years to income seems very pessimistic along with 'strong doubts' about a buy out on stunning news. As they are targeting people who have exhausted all treatments and they are already showing strong indications, I would say great results will be classified as spectacular. Happy to be the optimistic view to your doom mongering.
Well Digitalman you can make up for all the doom and gloom with your optimistic outlook. I recon that Dystopian's 10.48 post sums up Faron's exact position In every way. The only thing that may change things sooner Is that a Major Pharma
takes a liking to what Faron have to offer and buys the Co out. IMO.
Plenty of doom and gloom on offer today. Not long to see what the 20th May brings. Hopefuly spectacular data followed by a partnering announcement. Juho becomes the man of the hour!
Drac, I guess like all CEOs Marku had to put a rather optimistic spin on things but ultimately it just makes new investors very wary and only makes raising funds even more of a white knuckle ride. I would have more respect if CEOs just told it how it is, instead endless jam tomorrow stories..
Dystopian, exactly the way I see It. What sickens me Is Why did Markku make that SSV statement some years ago.
Any income stream Faron may get from Bex is 4-5 years away- this is the time scale to get through Phase 11, get approval for phase 111, get funded by whatever means possible , run phase 111 and finally get approval and then launch. Realistically the best we can hope for , medium term as investors ( everyones definition of this is different )is a partner to come in which will hopefully push the SP up. Then its decision time- wait for further developments or take profits - whichever way you cut it, its going to take years,-unless phase 11 is absolutely stunning- then a buyout may happen but I doubt it. Meanwhile Faron have a ton of money to raise.
It's, You think Faron would prefer to go It alone maybe looking for a Income stream? Of course they Need a an Income stream. Best of luck with that after the last little Hick Cup and NO explanation how It was allowed to happen. I won't hold my breath. Too many false dawns. Faron have No other option but to try and keep up whatever momentum Is left In the Co. What are they seeing In Bex ?. Is It Similiar to what they were seeing when they predicted SSV years ago?.
Feel free to correct me on any of the above. AIMO.
They must already know the results, just preparing the data yo be realised. If it wasn't gonna be good then why announce excellarating talks with the FDA.
Also, I think Faron would prefer to go it alone, there come this far already.. maybe they are looking at a income stream?
However, rally does a small pharma not need the big bucks from a whale..
I'm also invested in millions therapeutics and they have done a deal for 19% of the company to big pharma.
Either way.. Will 2024 be a pivotal year for us shareholders?
Good study 2 result,maybe Bayer do a bid?
Sounds good to me. 20th May phase 2 data to be important for ongoing partnering discussions. Does this mean a licensing deal is actually close now depending on those results? Hope so.
Really tempted to buy more at these low prices.. but they it's possible they will do a placing and if its public it could be at a discount...
Gonna wait and see
Trades at such very low amounts and have such a affect on the SP?. Anybody got a good reason?. IMO.
Anyone know ow what percentage is tradable on the markets ?
West,
Faron need some serious good news and SP Jolt to resurrect LTSHs from the pit they have left us In. IMO.
ATB.
Hi Drac,all the imvesters in Faron are now stuck awaiting the out come of the fund raise,Faron have stated that they are still pursuing the possibility of a non dilutive fund raise,but the dilution is already baked into the SP.If they do go down the route of non dilutive funding we may see a bounce of the SP.The main thing is that they get the P2 Bexmab study underway,and start releasing the Data.
Personally Faron have dropped to being just another typical AIM Co. The only difference Is the Major SHs that they managed to attract which IMO Is Impressive. How are those Investors feeling presently?. How can you decide where they are exactly with anything?. IMO.